The development is part of company’s mission to support patient access to clinical trials
News
Sanofi’s Xenpozyme approved by European Commission
Xenpozyme is a treatment for ASMD and the condition’s only current enzyme replacement therapy
Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor
Chronic myeloid leukaemia therapy Scemblix receives NICE final draft recommendation in Britain
Sirana enters into collaborative research agreement with Pfizer
Companies will combine to investigate a novel treatment for a rare bone disease
Atos opens Life Science Centre of Excellence
Centre will accelerate drug development and enable precision health solutions
First treatment for ‘broken heart syndrome’ trialled
Scientists will trial a programme of exercise conditioning and psychological therapy for people diagnosed with the condition
Avacta announces escalation in clinical study of AVA6000
AVA6000 is a novel form of doxorubicin that has been modified using Avacta’s delivery platform to improve safety
Amref and AstraZeneca launch clinics to support Kenyan COVID-19 vaccinations
The mobile clinics will support communities with limited or no access to vaccines and other health services
Novo Nordisk to build on heritage in rare blood disorders
New data will be released at the International Society on Thrombosis and Haemostasis Congress
AbbVie’s Rinvoq gains recommended approval by CHMP
CHMP returns positive opinion on Rinvoq for the treatment of adults with active non-radiographic axial spondyloarthritis
EU approves Norvatis’ Cosentyx for childhood arthritis
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
Sanofi and GSK report successful efficacy results against Omicron
COVID-19 Beta-containing vaccine provides 75.1% efficacy in participants previously infected with coronavirus
Positive MHRA decision for Briviact
MHRA extends UCB’s therapy for the treatment of partial-onset seizures
Pharma poised but no recorded monkeypox deaths
Global surveillance systems show that recorded cases do not include any deaths
Novartis invests $250m in malaria elimination commitment
The company has renewed its pledge to eliminate neglected tropical diseases and malaria over five years
